Quantcast
Last updated on April 20, 2014 at 7:58 EDT

Latest Palatin Technologies Inc. Stories

2014-03-31 16:27:19

CRANBURY, N.J., March 31, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in...

2014-03-06 08:30:39

CRANBURY, N.J., March 6, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26(th) Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs. A live audio broadcast will be...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...

2014-02-18 08:30:37

CRANBURY, N.J., Feb. 18, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013. Recent HighlightsPivotal Phase 3 clinical trials of bremelanotide for Female Sexual Dysfunction (FSD) are anticipated to start in the first half...

2014-02-13 08:30:33

Teleconference and Webcast to be held on February 18, 2014 CRANBURY, N.J., Feb. 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 18, 2014 at 11:00 a.m. ET. The conference call will include a review on...

2014-01-30 08:31:26

CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16(th) Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time. Dr. Michael L. Krychman from Southern California Center for...

2014-01-23 08:31:55

CRANBURY, N.J., Jan. 23, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program). This Program enables...

2014-01-16 16:24:19

CRANBURY, N.J., Jan. 16, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), announced today that Dr. Carl Spana, President and Chief Executive Officer, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 11:30 a.m. Eastern Time. A live audio and high-definition video webcast of Palatin's presentation and a copy of the presentation materials will be available...

2014-01-13 16:26:12

CRANBURY, N.J., Jan. 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) (the "Company") announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange") has contacted the Company in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on unusual market activity. About Palatin Technologies, Inc.Palatin Technologies, Inc. is a...

2013-12-02 16:23:37

CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25(th )Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace hotel in New York City. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live...